Defining a hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2531-2533

  Arai, Sally ^a   Fanale, Michelle ^b   Devos, Sven ^c   Engert, Andreas ^d   Illidge, Tim ^e   Borchmann, Peter ^d   Younes, Anas ^b   Morschhauser, Franck ^a   McMillan, Alex ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d German Hodgkin's Lymphoma Study Group   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; HODGKIN DISEASE; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE;

DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84885601064     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.798868     Document Type: Letter

References (15)

1. Diehi V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin?s disease. N Engi J Med 2003;348:2386-2395.
2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin?s disease: A randomised trial. Lancet 2002; 359:2065-207 1.
3. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma study group (GHSG). Ann Oncol 2005;16:116-123.
4. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin?s lymphoma. J Clin Oncol 2010;28:5074-5080.
5. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin?s lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group. Clin Oncol 2008;26:5980-5987.
6. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin?s disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) of the German Hodgkin study group (GHSG) and the working pary lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2005;23(16 Supplj: Abstract 6508.
7. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin?s disease: Analysis of the stanford university results and prognostic indices. Blood 1997;89:801-813.
8. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin?s disease: Analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997;20:21-26.
9. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97: 616-623.
10. Sureda A, Constans M, Iriondo A, et al. Prognostic factors aftècting long-term outcome after stem cell transplantation in Hodgkin?s lymphoma autografted after a first relapse. Ann Oncol 2005;16: 625-633.
11. Josting A, Franklin L May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin?s lymphoma registered in the database of the German Hodgkin?s lymphoma study group. J Clin Oncol 2002;20:221-230.
12. Younes A, GopalAK, Smith SE, et al. Results of the pivotal phase 11 study of brentuximab vedotin for patients with relapsed or refractory Hodgkin?s lymphoma. J Clin Oncol 2012;30:2183-2189.
13. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin?s lymphoma after autologous stem-cell transplantation: Results of a phase 11 study. J Clin Oncol 2012; 30:2197-203.
14. Fehniger TA, Larson 5, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-5125.
15. Si Leemhuis T, Wells 5, Scheftbld C, et al. A phase 1 trial of autologous cytokine-Induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11:181-187.